Sepsis detection in hematologic and solid tumor malignancies using quantitative inflammatory biomarker differences in a prospective single center study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11320%2F25%3A10512283" target="_blank" >RIV/00216208:11320/25:10512283 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Vd1WyBaJU0" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Vd1WyBaJU0</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41598-025-15784-1" target="_blank" >10.1038/s41598-025-15784-1</a>
Alternative languages
Result language
angličtina
Original language name
Sepsis detection in hematologic and solid tumor malignancies using quantitative inflammatory biomarker differences in a prospective single center study
Original language description
Sepsis is a life-threatening condition triggered by a dysregulated immune response to bloodstream infection. Patients with solid and hematologic malignancies are at increased risk of severe infections and the onset of sepsis. Due to the limitations of blood cultures, particularly in culture-negative sepsis, multiple serological biomarkers, such as C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), white blood cells (WBC), lymphocytes (LYM), neutrophils (NEU), and monocytes (MON), are frequently used to diagnose infections. This prospective observational study aims to evaluate the efficacy of these biomarkers in distinguishing sepsis in patients with hematologic and solid tumors. It was observed that hematologic cancer patients exhibited significantly elevated IL-6, PCT, and MON levels, indicating their strong potential for sepsis detection. However, this difference was not statistically significant in patients with solid cancers and sepsis. Specifically, patients with blood cancer at the onset of sepsis have elevated levels of IL-6, PCT and MON, with AUCs exceeding 0.75, indicating strong predictive value. In contrast, patients with solid tumors had a moderate but not statistically significant increase in PCT (AUC = 0.693). Biomarker combinations enhanced the diagnostic power for hematologic cancers, but their performance in solid tumors remained limited. The findings underscore the need for cancer-specific sepsis diagnostic approaches, with a particular focus on the unique immune dynamics of hematologic versus solid tumors.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10300 - Physical sciences
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Scientific Reports
ISSN
2045-2322
e-ISSN
2045-2322
Volume of the periodical
15
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
14
Pages from-to
31701
UT code for WoS article
001560945300002
EID of the result in the Scopus database
2-s2.0-105015019124